NEW YORK, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Talkspace (Nasdaq: TALK), a leading behavioral healthcare company, today announced that management will present and host one-on-one investor meetings at the 26th Annual Needham Growth Conference on January 16 and 19, 2024, virtually. The Company’s presentation will be on January 19, 2024, at 3:00pm EST.
To schedule a one-on-one meeting with management, please contact your Needham representative.
About Talkspace
Talkspace (Nasdaq: TALK) is a leading virtual behavioral healthcare company committed to helping people lead healthier, happier lives through access to high-quality mental healthcare. At Talkspace, we believe that mental healthcare is core to overall healthcare and should be available to everyone.
Talkspace pioneered the ability to text with a licensed therapist from anywhere and now offers a comprehensive suite of mental health services from self-guided products to individual and couples therapy, in addition to psychiatric treatment and medication management. With Talkspace’s core psychotherapy offering, members are matched with one of thousands of licensed providers across all 50 states and can choose from a variety of subscription plans including live video, text or audio chat sessions and/or asynchronous text messaging.
All care offered at Talkspace is delivered through an easy-to-use, fully-encrypted web and mobile platform that meets HIPAA, federal, and state regulatory requirements. Talkspace covers approximately 113 million lives as of September 30, 2023, through our partnerships with employers, health plans, and paid benefits programs.
For more information, visit www.talkspace.com.
Contacts
For Investors:
Neal Nagaragan
Sloane & Company
(301) 273-5662
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Media:
John Kim
SKDK
(310) 997-5963
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.19 |
Daily Change: | 0.03 0.95 |
Daily Volume: | 1,109,205 |
Market Cap: | US$538.850M |
December 10, 2024 October 29, 2024 September 04, 2024 August 06, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load